Last reviewed · How we verify
YL242; Pembrolizumab; 5-FU
At a glance
| Generic name | YL242; Pembrolizumab; 5-FU |
|---|---|
| Sponsor | MediLink Therapeutics (Suzhou) Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of YL242 in Subjects With Advanced Solid Tumors (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- YL242; Pembrolizumab; 5-FU CI brief — competitive landscape report
- YL242; Pembrolizumab; 5-FU updates RSS · CI watch RSS
- MediLink Therapeutics (Suzhou) Co., Ltd. portfolio CI